Literature DB >> 11805196

Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty.

Elizabeth Connolly1, David J Bouchier-Hayes, Elaine Kaye, Austin Leahy, Desmond Fitzgerald, Orina Belton.   

Abstract

Prostaglandin formation is enhanced in vascular disease, in part through induction of cyclooxygenase (COX-2) in vascular smooth muscle cells. Because COX regulates cell growth and migration, we examined whether the COX expression plays a role in the development of intimal hyperplasia after vascular injury. Rats undergoing balloon angioplasty of the carotid artery were randomized to receive a selective COX-2 inhibitor (SC-236), a selective COX-1 inhibitor (SC-560) or a combination of the two. Normal, uninjured vessels showed COX-1, but no COX-2 expression. Fourteen days after balloon injury, both COX-1 and COX-2 were expressed in the neointima. Balloon angioplasty resulted in a marked increase in the urinary excretion of prostaglandin (PG) E(2,) PGF(2alpha), and thromboxane (TX) B(2). Both the COX-1 inhibitor SC-560 and the COX-2 inhibitor SC-236 suppressed the generation of PGE(2) and PGF(2alpha), particularly when combined, suggesting a role for both isozymes in the generation of prostaglandins in this model. In contrast, TXA(2) was markedly suppressed by the COX-1 inhibitor SC-560. COX-2 inhibition with SC-236 had no effect on intimal hyperplasia at day 14 (0 versus 8.5%; n = 7 in controls). In contrast, intimal hyperplasia was reduced by SC-560 when administered alone (by 42%; n = 7, p < 0.05) or in combination with SC-236 (by 40%; n = 7, p < 0.05). COX-1 may play a role in the development of intimal hyperplasia, potentially through the inhibition of platelet TXA(2). Despite being expressed in the neointima, COX-2 does not play a role in the development of intimal hyperplasia after vascular injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805196     DOI: 10.1124/jpet.300.2.393

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

2.  Role of COX-2 in the bioactivation of methylenedianiline and in its proliferative effects in vascular smooth muscle cells.

Authors:  Valeria Y Hebert; Brandon Chad Jones; Randy C Mifflin; Tammy R Dugas
Journal:  Cardiovasc Toxicol       Date:  2011-12       Impact factor: 3.231

3.  Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.

Authors:  James L Park; Liming Shu; James A Shayman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

Review 4.  Vascular hyper-reactivity following arterial balloon injury: distant and delayed effects.

Authors:  Andrew J Wilson
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

5.  The balloon catheter induces an increase in contralateral carotid artery reactivity to angiotensin II and phenylephrine.

Authors:  D Accorsi-Mendonça; F M A Corrêa; T B Paiva; H P de Souza; F R M Laurindo; A M de Oliveira
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

6.  Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents.

Authors:  Won Ho Kim; Young-Guk Ko; Ki Woon Kang; Jung-Sun Kim; Byung-Keuk Kim; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.